Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 Apr;44(1):124–129. doi: 10.1128/iai.44.1.124-129.1984

Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease.

M E Klegerman, K M Boyer, C K Papierniak, L Levine, S P Gotoff
PMCID: PMC263480  PMID: 6423540

Abstract

Strain differences have been postulated to explain the observation that group B Streptococcus type III (GBS III) late-onset disease occurs in only a fraction of colonized infants. To determine the distribution of type-specific polysaccharide antigen (Ag) in GBS III, Ag was measured by rocket immunoelectrophoresis in both supernatant fluids and EDTA extracts and by radial immunodiffusion in multiple HCl extracts of the pellet from cultures of 10 strains of GBS III. Capsular Ag was defined as the sum of Ag in EDTA extracts + Ag in multiple HCl extracts. Both Ag in EDTA extracts and Ag in supernatant fluids correlated with capsular Ag (r = 0.94). GBS III strains were obtained from the blood of 19 infants with late-onset sepsis, from the cerebrospinal fluid or blood of 22 infants with late-onset meningitis, and from mucosal surfaces of both 18 infants and 12 mothers of infants with low levels of type-specific antibody and asymptomatic colonization. Mean values of Ag in supernatant fluids in strains from infants with late-onset sepsis (1.50 +/- 0.08 micrograms/ml) and late-onset meningitis (1.67 +/- 0.09 micrograms/ml) were significantly greater than those in asymptomatic colonization strains (1.14 +/- 0.05 micrograms/ml; P less than 0.001). The number of organisms required for a 50% lethal dose in the chick embryo, determined in 29 strains, was inversely related to Ag in supernatant fluids (r = -0.60). The demonstration that the quantity of capsular Ag produced by GBS III strains is related to their virulence in chick embryos and to their invasiveness in susceptible infants supports the hypothesis that Ag is a virulence factor in humans.

Full text

PDF
124

Images in this article

126Image
on p.126

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. doi: 10.1056/NEJM197604012941404. [DOI] [PubMed] [Google Scholar]
  2. Baker C. J., Kasper D. L., Davis C. E. Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med. 1976 Feb 1;143(2):258–270. doi: 10.1084/jem.143.2.258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baker C. J., Kasper D. L. Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun. 1976 Jan;13(1):189–194. doi: 10.1128/iai.13.1.189-194.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker C. J., Kasper D. L., Tager IRAB, Paredes A., Alpert S., McCormack W. M., Goroff D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest. 1977 May;59(5):810–818. doi: 10.1172/JCI108703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beachler C. W., Baker C. J., Kasper D. L., Fleming D. K., Webb B. J., Yow M. D. Group B streptococcal colonization and antibody status in lower socioeconomic parturient women. Am J Obstet Gynecol. 1979 Jan 15;133(2):171–173. doi: 10.1016/0002-9378(79)90470-8. [DOI] [PubMed] [Google Scholar]
  6. Carey R. B., Eisenstein T. K., Shockman G. D., Greber T. F., Swenson R. M. Soluble group- and type-specific antigens from type III group B Streptococcus. Infect Immun. 1980 Apr;28(1):195–203. doi: 10.1128/iai.28.1.195-203.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clamp J. R., Dawson G., Hough L. The simultaneous estimation of 6-deoxy-L-galactose (L-fucose), D-mannose, D-galactose, 2-acetamido-2-deoxy-D-glucose (N-acetyl-D-glucosamine) and N-acetylneuraminic acid (sialic acid) in glycopeptides and glycoproteins. Biochim Biophys Acta. 1967 Nov 28;148(2):342–349. doi: 10.1016/0304-4165(67)90129-8. [DOI] [PubMed] [Google Scholar]
  8. Doran T. I., Straus D. C., Mattingly S. J. Extracellular antigens of serotype III group B streptococci. Infect Immun. 1980 Dec;30(3):890–893. doi: 10.1128/iai.30.3.890-893.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Doran T. I., Straus D. C., Mattingly S. J. Factors influencing release of type III antigens by group B streptococci. Infect Immun. 1981 Feb;31(2):615–623. doi: 10.1128/iai.31.2.615-623.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Durham D. L., Mattingly S. J., Doran T. I., Milligan T. W., Straus D. C. Correlation between the production of extracellular substances by type III group B streptococcal strains and virulence in a mouse model. Infect Immun. 1981 Nov;34(2):448–454. doi: 10.1128/iai.34.2.448-454.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Edwards E. A. Immunologic investigations of meningococcal disease. I. Group-specific Neisseria meningitidis antigens present in the serum of patients with fulminant meningococcemia. J Immunol. 1971 Feb;106(2):314–317. [PubMed] [Google Scholar]
  12. Edwards M. S., Nicholson-Weller A., Baker C. J., Kasper D. L. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med. 1980 May 1;151(5):1275–1287. doi: 10.1084/jem.151.5.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. FAHEY J. L., MCKELVEY E. M. QUANTITATIVE DETERMINATION OF SERUM IMMUNOGLOBULINS IN ANTIBODY-AGAR PLATES. J Immunol. 1965 Jan;94:84–90. [PubMed] [Google Scholar]
  14. Hemming V. G., Hall R. T., Rhodes P. G., Shigeoka A. O., Hill H. R. Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence. J Clin Invest. 1976 Dec;58(6):1379–1387. doi: 10.1172/JCI108593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jennings H. J., Rosell K. G., Kasper D. L. Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem. 1980 Feb;58(2):112–120. doi: 10.1139/o80-016. [DOI] [PubMed] [Google Scholar]
  16. Kjems E., Perch B., Henrichsen J. Serotypes of group B streptococci and their relation to hyaluronidase production and hydrolysis of salicin. J Clin Microbiol. 1980 Feb;11(2):111–113. doi: 10.1128/jcm.11.2.111-113.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  18. MacLEOD C. M., KRAUS M. R. Relation of virulence of pneumococcal strains for mice to the quantity of capsular polysaccharide formed in vitro. J Exp Med. 1950 Jul 1;92(1):1–9. doi: 10.1084/jem.92.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Milligan T. W., Baker C. J., Straus D. C., Mattingly S. J. Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci. Infect Immun. 1978 Sep;21(3):738–746. doi: 10.1128/iai.21.3.738-746.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. RUSSELL B. E., SHERWOOD N. P. The role of hyaluronidase in experimental streptococcal infection. J Infect Dis. 1949 Jan-Feb;84(1):81–87. doi: 10.1093/infdis/84.1.81. [DOI] [PubMed] [Google Scholar]
  21. Santos J. I., Shigeoka A. O., Hill H. R. Strain differences in virulence of group B streptococci. Pediatr Res. 1982 May;16(5):347–350. doi: 10.1203/00006450-198205000-00005. [DOI] [PubMed] [Google Scholar]
  22. Sarff L. D., McCracken G. H., Schiffer M. S., Glode M. P., Robbins J. B., Orskov I., Orskov F. Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet. 1975 May 17;1(7916):1099–1104. doi: 10.1016/s0140-6736(75)92496-4. [DOI] [PubMed] [Google Scholar]
  23. Shigeoka A. O., Hall R. T., Hill H. R. Strain specificity of opsonins for group B streptococci types II and III. Infect Immun. 1979 Feb;23(2):438–445. doi: 10.1128/iai.23.2.438-445.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shigeoka A. O., Rote N. S., Santos J. I., Hill H. R. Assessment of the virulence factors of group B streptococci: correlation with sialic acid content. J Infect Dis. 1983 May;147(5):857–863. doi: 10.1093/infdis/147.5.857. [DOI] [PubMed] [Google Scholar]
  25. Straus D. C., Mattingly S. J., Milligan T. W., Doran T. I., Nealon T. J. Protease production by clinical isolates of type III group B streptococci. J Clin Microbiol. 1980 Sep;12(3):421–423. doi: 10.1128/jcm.12.3.421-423.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Summary of the workshop on perinatal infections due to group B Streptococcus. J Infect Dis. 1977 Jul;136(1):137–152. doi: 10.1093/infdis/136.1.137. [DOI] [PubMed] [Google Scholar]
  27. Tieffenberg J., Vogel L., Kretschmer R. R., Padnos D., Gotoff S. P. Chicken embryo model for type III group B beta-hemolytic streptococcal septicemia. Infect Immun. 1978 Feb;19(2):481–485. doi: 10.1128/iai.19.2.481-485.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Vogel L. C., Boyer K. M., Gadzala C. A., Gotoff S. P. Prevalence of type-specific group B streptococcal antibody in pregnant women. J Pediatr. 1980 Jun;96(6):1047–1051. doi: 10.1016/s0022-3476(80)80639-1. [DOI] [PubMed] [Google Scholar]
  29. Weeke B. Crossed immunoelectrophoresis. Scand J Immunol Suppl. 1973;1:47–56. doi: 10.1111/j.1365-3083.1973.tb03778.x. [DOI] [PubMed] [Google Scholar]
  30. Wilkinson H. W. Group B streptococcal infection in humans. Annu Rev Microbiol. 1978;32:41–57. doi: 10.1146/annurev.mi.32.100178.000353. [DOI] [PubMed] [Google Scholar]
  31. Wilkinson H. W., Moody M. D. Serological relationships of type I antigens of group B streptococci. J Bacteriol. 1969 Feb;97(2):629–634. doi: 10.1128/jb.97.2.629-634.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yogev R., Moxon E. R. Elaboration of type b capsule by Haemophilus influenzae as a determinant of pathogenicity and impaired killing by trimethoprim-sulfamethoxazole. J Clin Invest. 1982 Mar;69(3):658–665. doi: 10.1172/JCI110493. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES